Striving to provide balanced, scientific content related to care of patients with GU malignancies

Uromigos 2024 Year In Review

Uromigos in partnership with Topline Bio

#1 - ASCO GU: Highlights include KEYNOTE-564 which showed an overall survival advantage to adjuvant pembrolizumab for resected high-risk kidney cancer, adjuvant immunotherapy in resected bladder cancer and belzutifan in refractory RCC. The CONTACT-02 trial of cabozantinib + atezolizumab in prostate cancer is discussed in addition to emerging data with T cell engagers.

#2 - ASCO 2024: KIM-1 plasma biomarker data from the adjuvant atezolizumab study and RNAseq-based signatures from two of the IO/TKI phase 3 RCC trials are discussed. The data and press release regarding sacituzumab govitecan is highlighted in the context of ADC development in bladder cancer.

#3 - ESMO 1 (bladder and prostate): PEACE-3 (combination of enzalutamide/radium-223) is reviewed. The role of darolutamide in mHSPC, the emerging role of Pluvicto, the STAMPEDE trial analyses of metformin and estrogen patches, and the practice-changing NIAGARA study of neoadjuvant chemo/immunotherapy in bladder cancer are highlighted. THE SUNRISE program in bladder cancer is extensively discussed.

#4 ESMO 2 (RCC): The SUNNIFORECAST trial in non-clear cell RCC with Ipi/Nivo and the landscape of non-clear cell RCC therapeutics are discussed. The OS data for belzutifan in a refractory RCC setting and data on other HIF inhibitors is presented.

#5 - Uromigos Live: The 3rd Annual Uromigos Live 2024 from Nashville reviews sequential IO in RCC from the CONTACT and TiNivo-2 trials and salvage Ipi/Nivo and the emerging field of ADCs in bladder cancer. The Uromigos Cup competition was discussed including Team Japan and Tres Uramigas and the eventual winner Team USA. The Uromigos also discuss what clinical trial results they are looking forward to in 2025.

Watch All Topline x Uromigos Videos